JP2016527225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527225A5 JP2016527225A5 JP2016526580A JP2016526580A JP2016527225A5 JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5 JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016526580 A JP2016526580 A JP 2016526580A JP 2016527225 A5 JP2016527225 A5 JP 2016527225A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- kabat
- seq
- upa
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 17
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 8
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 4
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 230000002797 proteolythic effect Effects 0.000 claims 3
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13176519 | 2013-07-15 | ||
| EP13176519.0 | 2013-07-15 | ||
| US201361847664P | 2013-07-18 | 2013-07-18 | |
| US61/847,664 | 2013-07-18 | ||
| PCT/EP2014/065136 WO2015007727A1 (en) | 2013-07-15 | 2014-07-15 | Antibodies that bind urokinase plasminogen activator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016527225A JP2016527225A (ja) | 2016-09-08 |
| JP2016527225A5 true JP2016527225A5 (enExample) | 2017-08-10 |
Family
ID=48783103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526580A Withdrawn JP2016527225A (ja) | 2013-07-15 | 2014-07-15 | ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9908944B2 (enExample) |
| EP (1) | EP3022229A1 (enExample) |
| JP (1) | JP2016527225A (enExample) |
| CN (1) | CN105612183A (enExample) |
| TW (1) | TW201536810A (enExample) |
| WO (1) | WO2015007727A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| US11066482B2 (en) | 2017-09-21 | 2021-07-20 | Guy L. Reed | Specific plasmin inactivation by anticatalytic antibody |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| WO2020063823A1 (en) * | 2018-09-27 | 2020-04-02 | Zai Lab (Shanghai) Co., Ltd. | Anti-pd-1 antibodies and uses thereof |
| CN110343665B (zh) * | 2019-05-05 | 2023-07-14 | 吉林大学 | 一种car-t细胞及其应用 |
| AU2020373297A1 (en) * | 2019-10-28 | 2022-05-26 | Monash University | Antibodies for binding plasmin |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| WO2022171196A1 (zh) * | 2021-02-11 | 2022-08-18 | 兰州大学第二医院 | 抗cd87抗体及其特异性嵌合抗原受体 |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| WO2025227010A1 (en) * | 2024-04-26 | 2025-10-30 | Eli Lilly And Company | Protein tyrosine kinase 7 antibodies and antibody-drug conjugates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453269A (en) | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
| TW212184B (enExample) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| US8062637B2 (en) | 2000-05-08 | 2011-11-22 | Morphosys Ag | Methods of ameliorating inflammatory disease using an uPA antagonist |
| EP1406652A2 (en) | 2001-07-10 | 2004-04-14 | Omnio AB | Novel drug targets for arthritis |
| EP3960855A1 (en) * | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
| AU2004290585A1 (en) | 2003-11-18 | 2005-06-02 | Attenuon Llc | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| US8119128B2 (en) | 2004-10-29 | 2012-02-21 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor |
| EP2824183B1 (en) * | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| AU2012239997A1 (en) * | 2011-04-07 | 2013-10-17 | Amgen Inc. | Novel EGFR binding proteins |
-
2014
- 2014-07-15 EP EP14739165.0A patent/EP3022229A1/en not_active Withdrawn
- 2014-07-15 WO PCT/EP2014/065136 patent/WO2015007727A1/en not_active Ceased
- 2014-07-15 TW TW103124237A patent/TW201536810A/zh unknown
- 2014-07-15 US US14/905,409 patent/US9908944B2/en not_active Expired - Fee Related
- 2014-07-15 CN CN201480040491.0A patent/CN105612183A/zh not_active Withdrawn
- 2014-07-15 JP JP2016526580A patent/JP2016527225A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527225A5 (enExample) | ||
| JP2018510636A5 (enExample) | ||
| JP2019122405A5 (enExample) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| JP2016512551A5 (enExample) | ||
| HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
| JP2024056687A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| JP2013198490A5 (enExample) | ||
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP2013091655A5 (enExample) | ||
| NZ585559A (en) | Humanized antibodies against tl1a | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| JP2017052784A5 (enExample) | ||
| JP2017534577A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| NZ596042A (en) | Humanized anti-factor d antibodies | |
| JP2018527903A5 (enExample) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| WO2006103100A3 (en) | Antibodies against ccr5 and uses thereof | |
| JP2014512809A5 (enExample) |